Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: boosting the efficacy of intravenously administered therapeutic adenoviruses

  • Borrós, Salvador
  • Fornaguera, Cristina
  • Brugada Vilà, Pau
  • Fillat i Fonts, Cristina
  • Cascante, Anna
  • Lázaro, Miguel Ángel
  • Castells-Sala, Cristina
  • Rovira-Rigau, Maria
  • Albertazzi, Lorenzo
Oncolytic adenoviruses are used as agents for the treatment of cancer. However, their potential is limited due to the high seroprevalence of anti-adenovirus neutralizing antibodies (nAbs) within the population and the rapid liver sequestration when systemically administered. To overcome these challenges, we explored using nanoparticle formulation to boost the efficacy of systemic oncolytic adenovirus administration. Methods: Adenovirus were conjugated with PEGylated oligopeptide-modified poly(β-amino ester)s (OM-pBAEs). The resulting coated viral formulation was characterized in terms of surface charge, size, aggregation state and morphology and tested for anti-adenovirus nAbs evasion and activity in cancer cells. In vivo pharmacokinetics, biodistribution, tumor targeting, and immunogenicity studies were performed. The antitumor efficacy of the oncolytic adenovirus AdNuPARmE1A coated with OM-pBAEs (SAG101) in the presence of nAbs was evaluated in pancreatic ductal adenocarcinoma (PDAC) mouse models. Toxicity of the coated formulation was analyzed in vivo in immunocompetent mice. Results: OM-pBAEs conjugated to adenovirus and generated discrete nanoparticles with a neutral charge and an optimal size. The polymeric coating with the reporter AdGFPLuc (CPEG) showed enhanced transduction and evasion of antibody neutralization in vitro. Moreover, systemic intravenous administration of the formulation showed improved blood circulation and reduced liver sequestration, substantially avoiding activation of nAb production. OM-pBAEs coating of the oncolytic adenovirus AdNuPARmE1A (SAG101) improved its oncolytic activity in vitro and enhanced antitumor efficacy in PDAC mouse models. The coated formulation protected virions from neutralization by nAbs, as antitumor efficacy was preserved in their presence but was completely lost in mice that received the non-formulated AdNuPARmE1A. Finally, coated-AdNuPARmE1A showed reduced toxicity when high doses of the formulation were administered. Conclusions: The developed technology represents a promising improvement for future clinical cancer therapy using oncolytic adenoviruses.
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

CRISPR/Cas9-Mediated Knockin Application in Cell Therapy: A Non-viral Procedure for Bystander Treatment of Glioma in Mice

  • Meca Cortés, Oscar
  • Guerra-Rebollo, Marta
  • Garrido, Cristina
  • Borrós, Salvador
  • Rubio, Nuria
  • Blanco, Jeronimo
The use of non-viral procedures, together with CRISPR/Cas9 genome-editing technology, allows the insertion of single-copy therapeutic genes at pre-determined genomic sites, overcoming safety limitations resulting from random gene insertions of viral vectors with potential for genome damage. In this study, we demonstrate that combination of non-viral gene delivery and CRISPR/Cas9-mediated knockin via homology-directed repair can replace the use of viral vectors for the generation of genetically modified therapeutic cells. We custom-modified human adipose mesenchymal stem cells (hAMSCs), using electroporation as a transfection method and CRISPR/Cas9-mediated knockin for the introduction and stable expression of a 3 kb DNA fragment including the eGFP (selectable marker) and a variant of the herpes simplex virus 1 thymidine kinase genes (therapeutic gene), under the control of the human elongation factor 1 alpha promoter in exon 5 of the endogenous thymidine kinase 2 gene. Using a U87 glioma model in SCID mice, we show that the therapeutic capacity of the new CRISPR/Cas9-engineered hAMSCs is equivalent to that of therapeutic hAMSCs generated by introduction of the same therapeutic gene by transduction with a lentiviral vector previously published by our group. This strategy should be of general use to other applications requiring genetic modification of therapeutic cells., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Engineering oncogene-targeted anisamide-functionalized pBAE nanoparticles as efficient lung cancer antisense therapies

  • Fornaguera, Cristina
  • Torres-Coll, Antoni
  • Olmo, Laura
  • Garcia-Fernandez, Coral
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
Non-small cell lung cancer (NSCLC) is one of the leading causes of worldwide death, mainly due to the lack of efficient and safe therapies. Currently, NSCLC standard of care for consist on the use of traditional chemotherapeutics, non-selectively distributed through the whole body, thus causing severe side effects while not achieving high efficacy outcomes. Consequently, the need of novel therapies, targeted to modify specific subcellular routes aberrantly expressed only in tumor cells is still urgent. In this context, the delivery of siRNAs that can know-down overexpressed oncogenes, such as mTOR, could become the promised targeted therapy. However, siRNA effective delivery remains a challenge due to its compromised stability in biological fluids and its inability to cross biological and plasmatic membranes. Therefore, polymeric nanoparticles that efficiently encapsulate siRNAs and are selectively targeted to tumor cells could play a pivotal role. Accordingly, we demonstrate in this work that oligopeptide end-modified poly(beta aminoester) (OM-pBAE) polymers can efficiently complex siRNA in small nanometric particles using very low polymer amounts, protecting siRNA from nucleases attack. These nanoparticles are stable in the presence of serum, advantageous fact in terms of in vivo use. We also demonstrated that they efficiently transfect cells in vitro, in the presence of serum and are able to knock down target gene expression. Moreover, we demonstrated their antitumor efficacy by encapsulating mTOR siRNA, as a model antisense therapy, which showed specific lung tumor cell growth inhibition in vitro and in vivo. Finally, through the addition of anisamide functionalization to the surface of the nanoparticles, we proved that they become selective to lung tumor cells, while not affecting healthy cells. Therefore, our results are a first step in the discovery of a tumor cell-targeted efficient silencing nanotherapy for NSCLC patients survival improvement., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Efficient extracellular vesicles freeze-dry method for direct formulations preparation and use

  • Guarro, Mònica
  • Suñer, Francisca
  • Lecina, Martí
  • Borrós, Salvador
  • Fornaguera, Cristina
Despite the great knowledge achieved in the field of extracellular vesicles (EVs), the short lifetime of EVs liquid formulation still hampers the transfer of EVs technology to clinical applications. In this context, freeze-dried EVs would be advantageous thanks to the enhanced stability of solid formulations. Although some previous attempts have already been reported, the efficiency of EVs lyophilization methodologies used remains insufficient, and the characterization of the resulting EVs is still incomplete. The current work aims to describe an alternative and easy-to-be-applied methodology for EVs lyophilization. The use of sucrose as lyoprotectant at 8.5%wt improved the cryopreservation efficiency. After the subsequent cycles of freeze-drying, properties such as size, morphology, purity, EVs specific markers, biocompatibility and the maintenance of their functionality were confirmed in freeze-dried EVs samples. To sum up, we have designed a methodology for the lyophilization of extracellular vesicles that enables the preservation of the physicochemical properties and functionality of EVs., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy

  • Arista Romero, Maria
  • Cascante, Anna
  • Fornaguera, Cristina
  • Borrós, Salvador
Bladder cancer is the 10th most diagnosed cancer, with almost 10 M cancer deaths last year worldwide. Currently, chemotherapy is widely used as adjuvant therapy after surgical transurethral resection. Paclitaxel (PTX) is one of the most promising drugs, but cancer cells acquire resistance, causing failure of this treatment and increasing the recurrence of the disease. This poor chemotherapeutic response has been associated with the overexpression of the protein survivin. In this work, we present a novel dual nano-treatment for bladder cancer based on the hypothesis that the inhibition of survivin in cancer cells, using a siRNA gene therapy strategy, could decrease their resistance to PTX. For this purpose, two different polymeric nanoparticles were developed to encapsulate PTX and survivin siRNA independently. PTX nanoparticles showed sizes around 150 nm, with a paclitaxel loading of around 1.5%, that produced sustained tumor cell death. In parallel, siRNA nanoparticles, with similar sizes and loading efficiency of around 100%, achieved the oligonucleotide transfection and knocking down of survivin expression that also resulted in tumor cell death. However, dual treatment did not show the synergistic effect expected. The root cause of this issue was found to be the cell cycle arrest produced by nuclear survivin silencing, which is incompatible with PTX action. Therefore, we concluded that although the vastly reported role of survivin in bladder cancer, its silencing does not sensitize cells to currently applied chemotherapies., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

In Vivo Retargeting of Poly(beta aminoester) (OM-PBAE) Nanoparticles is Influenced by Protein Corona

  • Fornaguera, Cristina
  • Guerra-Rebollo, Marta
  • Lázaro, Miguel Ángel
  • Cascante, Anna
  • Rubio, Nuria
  • Blanco, Jeronimo
  • Borrós, Salvador
One of the main bottlenecks in the translation of nanomedicines from research to clinics is the difficulty in designing nanoparticles actively vectorized to the target tissue, a key parameter to ensure efficacy and safety. In this group, a library of poly(beta aminoester) polymers is developed, and it is demonstrated that adding specific combinations of terminal oligopeptides (OM-PBAE), in vitro transfection is cell selective. The current study aims to actively direct the nanoparticles to the liver by the addition of a targeting molecule. To achieve this objective, retinol, successfully attached to OM-PBAE, is selected as hepatic targeting moiety. It is demonstrated that organ biodistribution is tailored, achieving the desired liver accumulation. Regarding cell type transfection, antigen presenting cells in the liver are those showing the highest transfection. Thanks to proteomics studies, organ but not cellular biodistribution can be explained by the formation of differential protein coronas. Therefore, organ biodistribution is governed by differential protein corona formed when retinol is present, while cellular biodistribution is controlled by the end oligopeptides type. In summary, this work is a proof of concept that demonstrates the versatility of these OM-PBAE nanoparticles, in terms of the modification of the biodistribution of OM-PBAE nanoparticles adding active targeting moieties., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Application of an assay Cascade methodology for a deep preclinical characterization of polymeric nanoparticles as a treatment for gliomas

  • Fornaguera, Cristina
  • Lázaro, Miguel Ángel
  • Brugada Vilà, Pau
  • Porcar, Irene
  • Morera, Ingrid
  • Guerra-Rebollo, Marta
  • Garrido, Cristina
  • Blanco, Jeronimo
  • Cascante, Anna
  • Borrós, Salvador
Glioblastoma multiforme (GBM) is the most devastating primary brain tumor due to its infiltrating and diffuse growth characteristics, a situation compounded by the lack of effective treatments. Currently, many efforts are being devoted to find novel formulations to treat this disease, specifically in the nanomedicine field. However, due to the lack of comprehensive characterization that leads to insufficient data on reproducibility, only a reduced number of nanomedicines have reached clinical phases. In this context, the aim of the present study was to use a cascade of assays that evaluate from physical-chemical and structural properties to biological characteristics, both in vitro and in vivo, and also to check the performance of nanoparticles for glioma therapy. An amphiphilic block copolymer, composed of polyester and poly(ethylene glycol; PEG) blocks, has been synthesized. Using a mixture of this copolymer and a polymer containing an active targeting moiety to the Blood Brain Barrier (BBB; Seq12 peptide), biocompatible and biodegradable polymeric nanoparticles have been prepared and extensively characterized. In vitro studies demonstrated that nanoparticles are safe for normal cells but cytotoxic for cancer cells. In vivo studies in mice demonstrated the ability of the Seq12 peptide to cross the BBB. Finally, in vivo efficacy studies using a human tumor model in SCID mice resulted in a significant 50% life-span increase, as compared with non-treated animals. Altogether, this assay cascade provided extensive pre-clinical characterization of our polymeric nanoparticles, now ready for clinical evaluation., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SPIONs' Enhancer Effect on Cell Transfection: An Unexpected Advantage for an Improved Gene Delivery System

  • Balcells, Laura
  • Fornaguera, Cristina
  • Brugada-Vilà, Pau
  • Guerra-Rebollo, Marta
  • Meca-Cortés, Óscar
  • Martínez, Gema
  • Rubio, Núria
  • Blanco, Jerónimo
  • Santamaria, Jesus M.
  • Cascante, Anna
  • Borrós, Salvador
The clinical implantation of gene therapy is hindered by the limitations of current gene delivery vectors, namely, safety issues regarding viral vectors and low transfection efficacy regarding nonviral vectors. Thus, the design of safe and efficient gene carriers is a key point for the success of such therapies. In addition, when employing genetically modified cells for further applications, the selection of successfully modified cells becomes crucial. To address these issues, we have developed multicomponent nanoparticles composed of poly(ß-amino ester) (pBAE) polymers, plasmid DNA, and superparamagnetic iron oxide nanoparticles (SPIONs). Whereas pBAEs were initially employed as safe and biocompatible carriers with improved transfection efficiency, as compared to commercial vectors, SPIONs were used because of their magnetic character that enables cell selection. Surprisingly, the results presented here revealed an unexpected enhancer effect of SPIONs on the transfection efficiency of pBAE/pDNA polyplexes in both permissive and reluctant to transfection cell lines. This unanticipated outcome, together with the allowance to perform a selective magnetic sorting of genetically modified cells without interfering in cell transfection, opens the door to SPION-containing nanoparticles as promising tools for cell therapy approaches. © Copyright © 2019 American Chemical Society., Financial supports from MINECO/FEDER (grants RTC-2015-3751-1, SAF2015-64927-C2-1-R, and SAF2015-64927-C2-2-R) and Instituto de Salud Carlos III (Red Tematicá de Investigacioń Cooperativa en Terapia Celular-TERCEL and TRANSMAG transference project from CIBER-BBN) are acknowledged. CIBER-BBN is an initiative funded by the VI National R&D&I Plan2008−2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions, and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. L.B. is grateful to IQS for their Predoctoral Grant (Ajuts IQS pels Estudis de Doctrorat). C.F. is grateful to MINECO for their Postdoctoral Fellowship (grant Torres Quevedo 2015). The Support of Ageǹcia de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) from Generalitat de Catalunya is acknowledged for their support through SGR 2014 1170 grant., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Application of an assay Cascade methodology for a deep preclinical characterization of polymeric nanoparticles as a treatment for gliomas

  • Fornaguera, Cristina
  • Garrido, Cristina
  • Borrós, Salvador
Glioblastoma multiforme (GBM) is the most devastating primary brain tumor due to its infiltrating and diffuse growth characteristics, a situation compounded by the lack of effective treatments. Currently, many efforts are being devoted to find novel formulations to treat this disease, specifically in the nanomedicine field. However, due to the lack of comprehensive characterization that leads to insufficient data on reproducibility, only a reduced number of nanomedicines have reached clinical phases. In this context, the aim of the present study was to use a cascade of assays that evaluate from physical-chemical and structural properties to biological characteristics, both in vitro and in vivo, and also to check the performance of nanoparticles for glioma therapy. An amphiphilic block copolymer, composed of polyester and poly(ethylene glycol; PEG) blocks, has been synthesized. Using a mixture of this copolymer and a polymer containing an active targeting moiety to the Blood Brain Barrier (BBB; Seq12 peptide), biocompatible and biodegradable polymeric nanoparticles have been prepared and extensively characterized. In vitro studies demonstrated that nanoparticles are safe for normal cells but cytotoxic for cancer cells. In vivo studies in mice demonstrated the ability of the Seq12 peptide to cross the BBB. Finally, in vivo efficacy studies using a human tumor model in SCID mice resulted in a significant 50% life-span increase, as compared with non-treated animals. Altogether, this assay cascade provided extensive pre-clinical characterization of our polymeric nanoparticles, now ready for clinical evaluation. © 2017 The Author(s)., Financial support from MINECO/FEDER (grants RTC-2015-3751-1, SAF2015-64927-C2-1-R and SAF2015-64927-C2-2-R) and Instituto de Salud Carlos III (Red Temática de Investigación Cooperativa en Terapia Celular-TERCEL) are acknowledged. Cristina Fornaguera is grateful to MINECO for the Postdoctoral Fellowship (grant Torres Quevedo 2016)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CRISPR/Cas9-Mediated Knockin Application in Cell Therapy: A Non-viral Procedure for Bystander Treatment of Glioma in Mice

  • Meca-Cortés, Óscar
  • Guerra-Rebollo, Marta
  • Garrido, Cristina
  • Borrós, Salvador
  • Rubio, Núria
  • Blanco, Jerónimo
The use of non-viral procedures, together with CRISPR/Cas9 genome-editing technology, allows the insertion of single-copy therapeutic genes at pre-determined genomic sites, overcoming safety limitations resulting from random gene insertions of viral vectors with potential for genome damage. In this study, we demonstrate that combination of non-viral gene delivery and CRISPR/Cas9-mediated knockin via homology-directed repair can replace the use of viral vectors for the generation of genetically modified therapeutic cells. We custom-modified human adipose mesenchymal stem cells (hAMSCs), using electroporation as a transfection method and CRISPR/Cas9-mediated knockin for the introduction and stable expression of a 3 kb DNA fragment including the eGFP (selectable marker) and a variant of the herpes simplex virus 1 thymidine kinase genes (therapeutic gene), under the control of the human elongation factor 1 alpha promoter in exon 5 of the endogenous thymidine kinase 2 gene. Using a U87 glioma model in SCID mice, we show that the therapeutic capacity of the new CRISPR/Cas9-engineered hAMSCs is equivalent to that of therapeutic hAMSCs generated by introduction of the same therapeutic gene by transduction with a lentiviral vector previously published by our group. This strategy should be of general use to other applications requiring genetic modification of therapeutic cells. © 2017 The Author(s), This work was supported by MINECO/FEDER (grants SAF2015-64927-C2-1-R and SAF2015-64927-C2-2-R ) and the Instituto de Salud Carlos III (Red Temática de Investigación Cooperativa en Terapia Celular-TERCEL) . We would like to thank M.A. Pastor and C. Bestard (flow cytometry) for their excellent technical assistance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In Vivo Retargeting of Poly(beta aminoester) (OM-PBAE) Nanoparticles is Influenced by Protein Corona

  • Fornaguera, Cristina
  • Guerra-Rebollo, Marta
  • Lázaro, Miguel Ángel
  • Cascante, Anna
  • Rubio, Núria
  • Blanco, Jerónimo
  • Borrós, Salvador
One of the main bottlenecks in the translation of nanomedicines from research to clinics is the difficulty in designing nanoparticles actively vectorized to the target tissue, a key parameter to ensure efficacy and safety. In this group, a library of poly(beta aminoester) polymers is developed, and it is demonstrated that adding specific combinations of terminal oligopeptides (OM-PBAE), in vitro transfection is cell selective. The current study aims to actively direct the nanoparticles to the liver by the addition of a targeting molecule. To achieve this objective, retinol, successfully attached to OM-PBAE, is selected as hepatic targeting moiety. It is demonstrated that organ biodistribution is tailored, achieving the desired liver accumulation. Regarding cell type transfection, antigen presenting cells in the liver are those showing the highest transfection. Thanks to proteomics studies, organ but not cellular biodistribution can be explained by the formation of differential protein coronas. Therefore, organ biodistribution is governed by differential protein corona formed when retinol is present, while cellular biodistribution is controlled by the end oligopeptides type. In summary, this work is a proof of concept that demonstrates the versatility of these OM-PBAE nanoparticles, in terms of the modification of the biodistribution of OM-PBAE nanoparticles adding active targeting moieties. © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Financial support from Ministerio de Economía, Industria y Competitividad, Gobierno de España (grants RTC‐2015‐3751‐1, SAF2015‐64927‐C2‐1‐R, SAF2015‐64927‐C2‐2‐R, Torres Quevedo 2015, and RTI2018‐094734‐B‐C22) is acknowledged. C.F. is grateful to MINECO for their Postdoctoral Fellowship (grant Torres Quevedo 2015). The support of Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) from Generalitat de Catalunya through SGR 2017 1559 grant is also acknowledged. The authors acknowledge the kind support of Marco A. Fernández and Gerard Requena for the flow cytometry measures and analysis; Ramon Bartolí for the liver digestion experimental setup; and Júlia Meler, Irene Porcar, and Elena García‐Ollé for their kind support in some experiment performance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

mRNA Delivery System for Targeting Antigen-Presenting Cells In Vivo

  • Fornaguera, Cristina
  • Guerra-Rebollo, Marta
  • Lázaro, Miguel Ángel
  • Castells-Sala, Cristina
  • Meca-Cortés, Óscar
  • Ramos-Perez, Victor
  • Cascante, Anna
  • Rubio, Núria
  • Blanco, Jerónimo
  • Borrós, Salvador
The encapsulation of mRNA in nanosystems as gene vaccines for immunotherapy purposes has experienced an exponential increase in recent years. Despite the many advantages envisaged within these approaches, their application in clinical treatments is still limited due to safety issues. These issues can be attributed, in part, to liver accumulation of most of the designed nanosystems and to the inability to transfect immune cells after an intravenous administration. In this context, this study takes advantage of the known versatile properties of the oligopeptide end-modified poly (β-amino esters) (OM-PBAEs) to complex mRNA and form discrete nanoparticles. Importantly, it is demonstrated that the selection of the appropriate end-oligopeptide modifications enables the specific targeting and major transfection of antigen-presenting cells (APC) in vivo, after intravenous administration, thus enabling their use for immunotherapy strategies. Therefore, with this study, it can be confirmed that OM-PBAE are appropriate systems for the design of mRNA-based immunotherapy approaches aimed to in vivo transfect APCs and trigger immune responses to fight either tumors or infectious diseases. © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Financial support from MINECO/FEDER (grants RTC-2015-3751-1, SAF2015-64927-C2-1-R and SAF2015-64927-C2-2-R) and Instituto de Salud Carlos III (Red Temática de Investigación Cooperativa en Terapia Celular-TERCEL) are acknowledged. CIBER-BBN is an initiative funded by the VI National R&D&I Plan2008–2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. C.F. is grateful to MINECO for their Postdoctoral Fellowship (grant Torres Quevedo 2015). The Support of Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) from Generalitat de Catalunya for their support trough SGR 2014 1170 grant. Authors acknowledge the kind support of Marta Vives group on the digestion of spleens; Marco A. Fernández and Gerard Requena for the FACS measures and analysis and Irene Porcar and Elena García-Ollé for their kind support in experiments performance., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

SPIONs' Enhancer Effect on Cell Transfection: An Unexpected Advantage for an Improved Gene Delivery System

  • Balcells, L.
  • Fornaguera, C.
  • Brugada-Vilà, P.
  • Guerra-Rebollo, M.
  • Meca-Cortés, Ó.
  • Martínez, G.
  • Rubio, N.
  • Blanco, J.
  • Santamaría, J.
  • Cascante, A.
  • Borrós, S.
The clinical implantation of gene therapy is hindered by the limitations of current gene delivery vectors, namely, safety issues regarding viral vectors and low transfection efficacy regarding nonviral vectors. Thus, the design of safe and efficient gene carriers is a key point for the success of such therapies. In addition, when employing genetically modified cells for further applications, the selection of successfully modified cells becomes crucial. To address these issues, we have developed multicomponent nanoparticles composed of poly(ß-amino ester) (pBAE) polymers, plasmid DNA, and superparamagnetic iron oxide nanoparticles (SPIONs). Whereas pBAEs were initially employed as safe and biocompatible carriers with improved transfection efficiency, as compared to commercial vectors, SPIONs were used because of their magnetic character that enables cell selection. Surprisingly, the results presented here revealed an unexpected enhancer effect of SPIONs on the transfection efficiency of pBAE/pDNA polyplexes in both permissive and reluctant to transfection cell lines. This unanticipated outcome, together with the allowance to perform a selective magnetic sorting of genetically modified cells without interfering in cell transfection, opens the door to SPION-containing nanoparticles as promising tools for cell therapy approaches.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Application of an assay Cascade methodology for a deep preclinical characterization of polymeric nanoparticles as a treatment for gliomas

  • Fornaguera, Cristina
  • Lázaro, Miguel Ángel
  • Brugada Vilà, Pau
  • Porcar, Irene
  • Morera, Ingrid
  • Guerra-Rebollo, Marta
  • Garrido, Cristina
  • Blanco, Jeronimo
  • Cascante, Anna
  • Borrós, Salvador
Glioblastoma multiforme (GBM) is the most devastating primary brain tumor due to its infiltrating and diffuse growth characteristics, a situation compounded by the lack of effective treatments. Currently, many efforts are being devoted to find novel formulations to treat this disease, specifically in the nanomedicine field. However, due to the lack of comprehensive characterization that leads to insufficient data on reproducibility, only a reduced number of nanomedicines have reached clinical phases. In this context, the aim of the present study was to use a cascade of assays that evaluate from physical-chemical and structural properties to biological characteristics, both in vitro and in vivo, and also to check the performance of nanoparticles for glioma therapy. An amphiphilic block copolymer, composed of polyester and poly(ethylene glycol; PEG) blocks, has been synthesized. Using a mixture of this copolymer and a polymer containing an active targeting moiety to the Blood Brain Barrier (BBB; Seq12 peptide), biocompatible and biodegradable polymeric nanoparticles have been prepared and extensively characterized. In vitro studies demonstrated that nanoparticles are safe for normal cells but cytotoxic for cancer cells. In vivo studies in mice demonstrated the ability of the Seq12 peptide to cross the BBB. Finally, in vivo efficacy studies using a human tumor model in SCID mice resulted in a significant 50% life-span increase, as compared with non-treated animals. Altogether, this assay cascade provided extensive pre-clinical characterization of our polymeric nanoparticles, now ready for clinical evaluation., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy

  • Arista Romero, Maria
  • Cascante, Anna
  • Fornaguera, Cristina
  • Borrós, Salvador
Bladder cancer is the 10th most diagnosed cancer, with almost 10 M cancer deaths last year worldwide. Currently, chemotherapy is widely used as adjuvant therapy after surgical transurethral resection. Paclitaxel (PTX) is one of the most promising drugs, but cancer cells acquire resistance, causing failure of this treatment and increasing the recurrence of the disease. This poor chemotherapeutic response has been associated with the overexpression of the protein survivin. In this work, we present a novel dual nano-treatment for bladder cancer based on the hypothesis that the inhibition of survivin in cancer cells, using a siRNA gene therapy strategy, could decrease their resistance to PTX. For this purpose, two different polymeric nanoparticles were developed to encapsulate PTX and survivin siRNA independently. PTX nanoparticles showed sizes around 150 nm, with a paclitaxel loading of around 1.5%, that produced sustained tumor cell death. In parallel, siRNA nanoparticles, with similar sizes and loading efficiency of around 100%, achieved the oligonucleotide transfection and knocking down of survivin expression that also resulted in tumor cell death. However, dual treatment did not show the synergistic effect expected. The root cause of this issue was found to be the cell cycle arrest produced by nuclear survivin silencing, which is incompatible with PTX action. Therefore, we concluded that although the vastly reported role of survivin in bladder cancer, its silencing does not sensitize cells to currently applied chemotherapies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In Vivo Retargeting of Poly(beta aminoester) (OM-PBAE) Nanoparticles is Influenced by Protein Corona

  • Fornaguera, Cristina
  • Guerra-Rebollo, Marta
  • Lázaro, Miguel Ángel
  • Cascante, Anna
  • Rubio, Nuria
  • Blanco, Jeronimo
  • Borrós, Salvador
One of the main bottlenecks in the translation of nanomedicines from research to clinics is the difficulty in designing nanoparticles actively vectorized to the target tissue, a key parameter to ensure efficacy and safety. In this group, a library of poly(beta aminoester) polymers is developed, and it is demonstrated that adding specific combinations of terminal oligopeptides (OM-PBAE), in vitro transfection is cell selective. The current study aims to actively direct the nanoparticles to the liver by the addition of a targeting molecule. To achieve this objective, retinol, successfully attached to OM-PBAE, is selected as hepatic targeting moiety. It is demonstrated that organ biodistribution is tailored, achieving the desired liver accumulation. Regarding cell type transfection, antigen presenting cells in the liver are those showing the highest transfection. Thanks to proteomics studies, organ but not cellular biodistribution can be explained by the formation of differential protein coronas. Therefore, organ biodistribution is governed by differential protein corona formed when retinol is present, while cellular biodistribution is controlled by the end oligopeptides type. In summary, this work is a proof of concept that demonstrates the versatility of these OM-PBAE nanoparticles, in terms of the modification of the biodistribution of OM-PBAE nanoparticles adding active targeting moieties., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficient extracellular vesicles freeze-dry method for direct formulations preparation and use

  • Guarro, Mònica
  • Suñer, Francisca
  • Lecina, Martí
  • Borrós, Salvador
  • Fornaguera, Cristina
Despite the great knowledge achieved in the field of extracellular vesicles (EVs), the short lifetime of EVs liquid formulation still hampers the transfer of EVs technology to clinical applications. In this context, freeze-dried EVs would be advantageous thanks to the enhanced stability of solid formulations. Although some previous attempts have already been reported, the efficiency of EVs lyophilization methodologies used remains insufficient, and the characterization of the resulting EVs is still incomplete. The current work aims to describe an alternative and easy-to-be-applied methodology for EVs lyophilization. The use of sucrose as lyoprotectant at 8.5%wt improved the cryopreservation efficiency. After the subsequent cycles of freeze-drying, properties such as size, morphology, purity, EVs specific markers, biocompatibility and the maintenance of their functionality were confirmed in freeze-dried EVs samples. To sum up, we have designed a methodology for the lyophilization of extracellular vesicles that enables the preservation of the physicochemical properties and functionality of EVs., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: boosting the efficacy of intravenously administered therapeutic adenoviruses

  • Borrós, Salvador
  • Fornaguera, Cristina
  • Brugada Vilà, Pau
  • Fillat i Fonts, Cristina
  • Cascante, Anna
  • Lázaro, Miguel Ángel
  • Castells-Sala, Cristina
  • Rovira-Rigau, Maria
  • Albertazzi, Lorenzo
Oncolytic adenoviruses are used as agents for the treatment of cancer. However, their potential is limited due to the high seroprevalence of anti-adenovirus neutralizing antibodies (nAbs) within the population and the rapid liver sequestration when systemically administered. To overcome these challenges, we explored using nanoparticle formulation to boost the efficacy of systemic oncolytic adenovirus administration. Methods: Adenovirus were conjugated with PEGylated oligopeptide-modified poly(β-amino ester)s (OM-pBAEs). The resulting coated viral formulation was characterized in terms of surface charge, size, aggregation state and morphology and tested for anti-adenovirus nAbs evasion and activity in cancer cells. In vivo pharmacokinetics, biodistribution, tumor targeting, and immunogenicity studies were performed. The antitumor efficacy of the oncolytic adenovirus AdNuPARmE1A coated with OM-pBAEs (SAG101) in the presence of nAbs was evaluated in pancreatic ductal adenocarcinoma (PDAC) mouse models. Toxicity of the coated formulation was analyzed in vivo in immunocompetent mice. Results: OM-pBAEs conjugated to adenovirus and generated discrete nanoparticles with a neutral charge and an optimal size. The polymeric coating with the reporter AdGFPLuc (CPEG) showed enhanced transduction and evasion of antibody neutralization in vitro. Moreover, systemic intravenous administration of the formulation showed improved blood circulation and reduced liver sequestration, substantially avoiding activation of nAb production. OM-pBAEs coating of the oncolytic adenovirus AdNuPARmE1A (SAG101) improved its oncolytic activity in vitro and enhanced antitumor efficacy in PDAC mouse models. The coated formulation protected virions from neutralization by nAbs, as antitumor efficacy was preserved in their presence but was completely lost in mice that received the non-formulated AdNuPARmE1A. Finally, coated-AdNuPARmE1A showed reduced toxicity when high doses of the formulation were administered. Conclusions: The developed technology represents a promising improvement for future clinical cancer therapy using oncolytic adenoviruses.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CRISPR/Cas9-Mediated Knockin Application in Cell Therapy: A Non-viral Procedure for Bystander Treatment of Glioma in Mice

  • Meca Cortés, Oscar
  • Guerra-Rebollo, Marta
  • Garrido, Cristina
  • Borrós, Salvador
  • Rubio, Nuria
  • Blanco, Jeronimo
The use of non-viral procedures, together with CRISPR/Cas9 genome-editing technology, allows the insertion of single-copy therapeutic genes at pre-determined genomic sites, overcoming safety limitations resulting from random gene insertions of viral vectors with potential for genome damage. In this study, we demonstrate that combination of non-viral gene delivery and CRISPR/Cas9-mediated knockin via homology-directed repair can replace the use of viral vectors for the generation of genetically modified therapeutic cells. We custom-modified human adipose mesenchymal stem cells (hAMSCs), using electroporation as a transfection method and CRISPR/Cas9-mediated knockin for the introduction and stable expression of a 3 kb DNA fragment including the eGFP (selectable marker) and a variant of the herpes simplex virus 1 thymidine kinase genes (therapeutic gene), under the control of the human elongation factor 1 alpha promoter in exon 5 of the endogenous thymidine kinase 2 gene. Using a U87 glioma model in SCID mice, we show that the therapeutic capacity of the new CRISPR/Cas9-engineered hAMSCs is equivalent to that of therapeutic hAMSCs generated by introduction of the same therapeutic gene by transduction with a lentiviral vector previously published by our group. This strategy should be of general use to other applications requiring genetic modification of therapeutic cells., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Engineering oncogene-targeted anisamide-functionalized pBAE nanoparticles as efficient lung cancer antisense therapies

  • Fornaguera, Cristina
  • Torres-Coll, Antoni
  • Olmo, Laura
  • Garcia-Fernandez, Coral
  • Guerra-Rebollo, Marta
  • Borrós, Salvador
Non-small cell lung cancer (NSCLC) is one of the leading causes of worldwide death, mainly due to the lack of efficient and safe therapies. Currently, NSCLC standard of care for consist on the use of traditional chemotherapeutics, non-selectively distributed through the whole body, thus causing severe side effects while not achieving high efficacy outcomes. Consequently, the need of novel therapies, targeted to modify specific subcellular routes aberrantly expressed only in tumor cells is still urgent. In this context, the delivery of siRNAs that can know-down overexpressed oncogenes, such as mTOR, could become the promised targeted therapy. However, siRNA effective delivery remains a challenge due to its compromised stability in biological fluids and its inability to cross biological and plasmatic membranes. Therefore, polymeric nanoparticles that efficiently encapsulate siRNAs and are selectively targeted to tumor cells could play a pivotal role. Accordingly, we demonstrate in this work that oligopeptide end-modified poly(beta aminoester) (OM-pBAE) polymers can efficiently complex siRNA in small nanometric particles using very low polymer amounts, protecting siRNA from nucleases attack. These nanoparticles are stable in the presence of serum, advantageous fact in terms of in vivo use. We also demonstrated that they efficiently transfect cells in vitro, in the presence of serum and are able to knock down target gene expression. Moreover, we demonstrated their antitumor efficacy by encapsulating mTOR siRNA, as a model antisense therapy, which showed specific lung tumor cell growth inhibition in vitro and in vivo. Finally, through the addition of anisamide functionalization to the surface of the nanoparticles, we proved that they become selective to lung tumor cells, while not affecting healthy cells. Therefore, our results are a first step in the discovery of a tumor cell-targeted efficient silencing nanotherapy for NSCLC patients survival improvement., info:eu-repo/semantics/publishedVersion